Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NAUT Nautilus Biotechnology Inc
- Stocks
- Healthcare
- NASDAQ: NAUT
Price (delayed)
$0.7749
Market cap
$97.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.54
Enterprise value
$93.86M
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics
Highlights
Nautilus Biotechnology's debt has decreased by 13% YoY and by 3.7% QoQ
NAUT's EPS is up by 3.6% since the previous quarter
The equity has decreased by 22% YoY and by 7% from the previous quarter
The quick ratio has contracted by 14% YoY
Key stats
What are the main financial stats of NAUT
Market
Valuations
Earnings
Shares outstanding
126.15M
Market cap
$97.75M
Enterprise value
$93.86M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.5
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$78.71M
Net income
-$68.66M
EBIT
-$68.66M
EBITDA
-$62.28M
Free cash flow
-$58.51M
Per share
Balance sheet
Liquidity
EPS
-$0.54
EPS diluted
-$0.54
Free cash flow per share
-$0.46
Book value per share
$1.54
Revenue per share
$0
TBVPS
$1.8
Total assets
$227.69M
Total liabilities
$33.26M
Debt
$29.34M
Equity
$194.44M
Working capital
$133.45M
Debt to equity
0.15
Current ratio
17.36
Quick ratio
17.02
Net debt/EBITDA
0.06
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-27.4%
Return on equity
-31.9%
Return on invested capital
-27.4%
Return on capital employed
-31.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NAUT stock price
How has the Nautilus Biotechnology stock price performed over time
Intraday
0.92%
1 week
4.36%
1 month
14.39%
1 year
-69.97%
YTD
-53.88%
QTD
-10%
Financial performance
How have Nautilus Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$78.71M
Net income
-$68.66M
Gross margin
N/A
Net margin
N/A
Nautilus Biotechnology's net income has increased by 3% QoQ
Nautilus Biotechnology's operating income has increased by 3.4% from the previous quarter
Price vs fundamentals
How does NAUT's price correlate with its fundamentals
Growth
What is Nautilus Biotechnology's growth rate over time
Valuation
What is Nautilus Biotechnology stock price valuation
P/E
N/A
P/B
0.5
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NAUT's EPS is up by 3.6% since the previous quarter
The stock's price to book (P/B) is 87% less than its 5-year quarterly average of 3.8 and 55% less than its last 4 quarters average of 1.1
The equity has decreased by 22% YoY and by 7% from the previous quarter
Efficiency
How efficient is Nautilus Biotechnology business performance
The return on equity has declined by 28% year-on-year and by 3.2% since the previous quarter
NAUT's return on assets is down by 26% year-on-year and by 3% since the previous quarter
The ROIC is down by 18% year-on-year and by 4.2% since the previous quarter
Dividends
What is NAUT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NAUT.
Financial health
How did Nautilus Biotechnology financials performed over time
Nautilus Biotechnology's total assets has decreased by 21% YoY and by 6% from the previous quarter
NAUT's total liabilities is down by 15% year-on-year and by 2.2% since the previous quarter
Nautilus Biotechnology's debt is 85% lower than its equity
The equity has decreased by 22% YoY and by 7% from the previous quarter
Nautilus Biotechnology's debt to equity has increased by 15% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.